BCAT-IN-4 - An Overview
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze To guage several intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Most important trial aims were being to evaluate the protection and tolerability of sifalimumab in dermatomyositis